GlassScriptPhysician profile
Connie A Duda
NPI 1881669760
$5,364.66
in general payments reported to CMS, 2019-2025
31 companies · $1,468 in 2025
The $1,468 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,131 · 2022: $833 · 2023: $931 · 2024: $1,001 · 2025: $1,468.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,400.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,400.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,216.73 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $542.25 | 2021-2025 | Wegovy, Ozempic |
| Sanofi-Aventis U.S. LLC | $491.03 | 2021-2022 | |
| Abbott Laboratories | $429.75 | 2023-2025 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $394.95 | 2022-2025 | Arexvy, Shingrix |
| Scpharmaceuticals INC. | $250.16 | 2025 | |
| Phathom Pharmaceuticals, INC. | $199.70 | 2025 | Voquezna |
| Pfizer INC. | $195.03 | 2021-2022 | |
| Nestle Healthcare Nutrition INC. | $166.10 | 2022-2023 | |
| Aimmune Therapeutics, INC. | $153.86 | 2024 | |
| Medtronic, INC. | $132.00 | 2023 | Corevalve Evolut R |
| Amgen INC. | $121.18 | 2025 | Evenity |
| Axsome Therapeutics, INC. | $115.88 | 2025 | Symbravo |
| Astellas Pharma US INC | $115.76 | 2022-2023 | Veozah |
| Lilly USA, LLC | $107.71 | 2021-2023 | Mounjaro |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $107.15 | 2022-2024 | |
| Eisai INC. | $89.90 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $80.41 | 2022 | |
| Esperion Therapeutics, INC. | $67.32 | 2021 | |
| Genentech USA, INC. | $59.21 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $51.23 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $43.70 | 2021 | |
| Dexcom, INC. | $38.77 | 2024 | Dexcom G7 Gss (161) |
| Acerus Pharmaceuticals Corporation | $31.60 | 2021 | |
| Idorsia Pharmaceuticals US INC | $31.12 | 2022-2023 | Quviviq |
| Merck Sharp & Dohme LLC | $29.40 | 2021 | |
| Gilead Sciences, INC. | $25.68 | 2025 | |
| Scynexis, INC. | $22.25 | 2022 | |
| Vbi Vaccine (Delaware) INC. | $21.79 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.80 | 2023 | Trulance, Xifaxan |
| Dynavax Technologies Corporation | $16.24 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Connie Duda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.